What you need to know
John Theurer Cancer Center at Hackensack University Medical Center is recruiting for WIZARD 201G, a global Phase 2 study in glioblastoma (GBM).
The trial is sponsored by Boston Biomedical and is evaluating DSP-7888, an investigational cancer vaccine, in combination with bevacizumab for recurrent disease.
More details on DSP-7888
DSP-7888 is being developed by Biomedical, Inc. It is hypothesized to induce Wilms’ tumor gene 1 (WT1)-specific cytotoxic T lymphocytes and helper T cells to attack WT1-expressing cancer cells found in various cancers.
In the multicenter, global Phase 2 WIZARD 201G study, patients receive either DSP-7888 in combination with bevacizumab or bevacizumab alone. The primary objectives of the study are to determine the safety and tolerability of DSP-7888 as well as overall survival.
The trial is expected to enroll approximately 200 patients and is being conducted at sites in the United States, Canada, Japan, Korea and Taiwan.
For more information
For study criteria and additional information, click here or contact:
- Phone: 844-904-7088
- Email: US122@xfactorbbi.com
For general information about clinical trials at John Theurer Cancer Center, visit www.jtcancercenter.org or call 551-996-5834.